Based in Alberta, the cutting-edge biotechnology company Resverlogix has enjoyed a 174% share price boost since 2016. Late-stage clinical testing of niche treatments is Resverlogix’s area of growth, with a compound called apabetalone aimed at the cardiovascular disease market attracting investors’ attention.

However, by a cruel twist of fate, the recent announcement of Resverlogix’s place on the TSX30 was followed almost immediately by news that its therapy, BETonMACE, had not met expectations. Investors ditched the pharma company when it transpired that the drug failed to reduce certain key cardiovascular events. The stock dropped almost 70% as a result.

Investors looking for a safer bet, and one that taps directl.....

https://www.fool.ca/2019/10/07/which-healthcare-stocks-should-you-buy-for-rrsp-growth/